Frazier Life Sciences Management’s Lexeo Therapeutics LXEO Stock Holding History

Frazier Life Sciences Management’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.5M	Buy	4,824,725 +400,000	+9%	+$2.16M	0.49%	33
2026 Q1	$25.4M	Hold	4,424,725	–	–	0.65%	26
2025 Q4	$43.9M	Hold	4,424,725	–	–	1.18%	21
2025 Q3	$29.4M	Hold	4,424,725	–	–	0.88%	25
2025 Q2	$17.8M	Buy	4,424,725 +3,469,210	+363%	+$11.4M	0.71%	29
2025 Q1	$3.32M	Hold	955,515	–	–	0.15%	45
2024 Q4	$6.29M	Sell	955,515 -295,271	-24%	-$2.33M	0.26%	44
2024 Q3	$11.3M	Buy	+1,250,786	New	+$14.9M	0.45%	36

Other funds holding LXEO

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jupiter Topco New York $245B AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Frazier Life Sciences Management's LXEO Position: Q2 2026 in Review

Frazier Life Sciences Management increased its Lexeo Therapeutics (LXEO) stake by 9% in Q2 2026, buying an estimated $2.16M and bringing the position to 4,824,725 shares worth $22.5M. The position accounts for 0.49% of the portfolio, ranked #33.

Frazier Life Sciences Management first reported a position in LXEO in Q3 2024 and has held it in 8 quarters since. The position peaked at $43.9M in Q4 2025. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

Frazier Life Sciences Management held 4,824,725 shares of Lexeo Therapeutics worth $22.5M as of Q2 2026.
Frazier Life Sciences Management bought 400,000 Lexeo Therapeutics shares in Q2 2026, an estimated $2.16M.
Lexeo Therapeutics made up 0.49% of Frazier Life Sciences Management's portfolio in Q2 2026, its #33 holding.
Frazier Life Sciences Management first reported a position in Lexeo Therapeutics in Q3 2024 and has held it in 8 quarters since.
Frazier Life Sciences Management's Lexeo Therapeutics position peaked at $43.9M in Q4 2025.
142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.